• Explore /
  • Poster
  • / Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy In patients (pts) with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy In patients (pts) with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.

Abstract Poster

Authors

null

Federica Morano

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Federica Morano , Monica Niger , Salvatore Corallo , Sara Lonardi , Stefano Tamberi , Samantha Di Donato , Elisa Giommoni , Francesco Giuliani Sr., Giovanni Luca Frassineti , Gianluca Tomasello , Ferdinando De Vita , Giovanni Gerardo Cardellino , Graziella Pinotti , Maria Pia Brizzi , Lorenza Rimassa , Mario Scartozzi , Rossana Berardi , Filippo G. De Braud , Filippo Pietrantonio , Maria Di Bartolomeo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02934464

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS4151)

DOI

10.1200/JCO.2019.37.15_suppl.TPS4151

Abstract #

TPS4151

Poster Bd #

251a

Abstract Disclosures

Similar Posters

First Author: Zev A. Wainberg

First Author: Ryan Sugarman

First Author: Rui-hua Xu

First Author: Lin Shen